DK3538157T3 - Methylglyoxal-fjernende cykliske peptider og deres anvendelse til forebyggelse og behandling af sygdomme, der er forbundet med forhøjede methylglyoxal-niveauer - Google Patents

Methylglyoxal-fjernende cykliske peptider og deres anvendelse til forebyggelse og behandling af sygdomme, der er forbundet med forhøjede methylglyoxal-niveauer Download PDF

Info

Publication number
DK3538157T3
DK3538157T3 DK17797917.6T DK17797917T DK3538157T3 DK 3538157 T3 DK3538157 T3 DK 3538157T3 DK 17797917 T DK17797917 T DK 17797917T DK 3538157 T3 DK3538157 T3 DK 3538157T3
Authority
DK
Denmark
Prior art keywords
methylglyoxal
prevention
treatment
diseases related
increased
Prior art date
Application number
DK17797917.6T
Other languages
English (en)
Inventor
Sebastian Brings
Thomas H Fleming
Walter Mier
Peter P Nawroth
Original Assignee
Ruprecht Karls Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ruprecht Karls Univ filed Critical Ruprecht Karls Univ
Application granted granted Critical
Publication of DK3538157T3 publication Critical patent/DK3538157T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Optics & Photonics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
DK17797917.6T 2016-11-10 2017-11-06 Methylglyoxal-fjernende cykliske peptider og deres anvendelse til forebyggelse og behandling af sygdomme, der er forbundet med forhøjede methylglyoxal-niveauer DK3538157T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16198096 2016-11-10
PCT/EP2017/078298 WO2018087028A1 (en) 2016-11-10 2017-11-06 Methylglyoxal-scavenging cyclic peptides and their use for the prevention and treatment of diseases associated with elevated methylglyoxal levels

Publications (1)

Publication Number Publication Date
DK3538157T3 true DK3538157T3 (da) 2022-07-04

Family

ID=57286299

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17797917.6T DK3538157T3 (da) 2016-11-10 2017-11-06 Methylglyoxal-fjernende cykliske peptider og deres anvendelse til forebyggelse og behandling af sygdomme, der er forbundet med forhøjede methylglyoxal-niveauer

Country Status (5)

Country Link
US (1) US11202833B2 (da)
EP (1) EP3538157B1 (da)
DK (1) DK3538157T3 (da)
ES (1) ES2920146T3 (da)
WO (1) WO2018087028A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4268890A1 (en) * 2022-04-28 2023-11-01 Universität Heidelberg Methylglyoxal-scavenging cyclic peptides and their use for the prevention and treatment of diseases associated with elevated methylglyoxal levels
WO2024031084A2 (en) * 2022-08-05 2024-02-08 The Texas A&M University System Compositions and methods for dye-bound cyclized peptides for medical use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011012742A (es) 2009-05-29 2012-05-22 Univ Ruprecht Karls Heidelberg Compuestos depuradores de metilglioxal y su uso para la prevencion y tratamiento de dolor y/o hiperalgesia.
WO2011095218A1 (en) 2010-02-05 2011-08-11 Polyphor Ag Template-fixed pep tidomime tics with cxcr7 modulating activity

Also Published As

Publication number Publication date
ES2920146T3 (es) 2022-08-01
WO2018087028A1 (en) 2018-05-17
US20190282700A1 (en) 2019-09-19
US11202833B2 (en) 2021-12-21
EP3538157B1 (en) 2022-05-18
EP3538157A1 (en) 2019-09-18

Similar Documents

Publication Publication Date Title
DK3673080T3 (da) Antisense-oligomerer til behandling af lidelser og sygdomme
DK3889145T3 (da) 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme
DK3285803T3 (da) Fremgangsmåder til behandling eller forebyggelse af migrænehovedpine
DK3317286T3 (da) Cykliserede sulfamoylarylamidderivater og anvendelse deraf som medikamenter til behandling af hepatitis b
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
DK3349758T3 (da) Fremgangsmåder til behandling af arenaviridae-virusinfektioner
DK3407889T3 (da) Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet
DK3472183T5 (da) Variant adeno-associerede virus og fremgangsmåder til anvendelse
DK3173092T3 (da) Rna-holdig sammensætning til behandling af tumorsygdomme
DK3160476T3 (da) Substituerede nukleosider, nukleotider og analoger dertil til anvendelse til behandling af virusinfektioner
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3372229T3 (da) Fremgangsmåder til øgning af tonisk hæmning og behandling af angelmans syndrom
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3303339T3 (da) Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK3294283T3 (da) Sacubitril-valsartan-doseringsregime til behandling af hjerteinsufficiens
DK3189074T3 (da) Sammensætninger og metoder til behandling og forebyggelse af inflammation
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3294345T3 (da) Tpp1-formuleringer og fremgangsmåder til behandling af cln2-sygdom
DK3142664T3 (da) Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme
DK3310190T3 (da) Sammensætning til behandling af kød og anvendelse af denne
DK3294740T3 (da) Hidtil ukendte sulfonimidoylpurinonforbindelser og derivater til behandling og profylakse af virusinfektion
DK3328864T3 (da) Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser